Silexion Reports Breakthrough Preclinical Results for KRAS-Targeted Cancer Therapy SIL204

Silexion’s Robust Preclinical Data Dhowed Excellent Results

Announcement

Silexion Therapeutics Corp., a global clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-targeted cancers, revealed excellent new preclinical data results, stating the inhibition rates of 97% in pancreatic cancer cells and 90% in colorectal cancer cells. These findings are a recognition of the company’s first evidence of safety and efficacy against its clinically prominent KRAS Q61H mutation in human cancer cells. It demonstrates a commendable advancement from previously released report results and develops SIL204’s ability as a pan-KRAS therapeutic. This is a development of the company’s previous reports and a contribution to the ongoing clinical trials. The severity of this condition needs precise treatments and medicines; these remarkable results of the preclinical trial have raised expectations of a valuable treatment in the healthcare market.

Evidence from the Previous Report Activities

The company addressed activities in several cancer models. The latest discovery of the study from a comprehensive CTG (Cell Titer-Glo) analysis elaborates proficiency in inhibition rates and enables the first-ever direct comparison of SIL204’s potential in various KRAS mutations and cancer types in a single study. Also, including dose-dependent inhibition of up to 94% in pancreatic cancer cells with KRAS G12D mutations, shows compared inhibition rates of 07% in pancreatic cells with the firstly untested KRAS Q61H mutation.

Views and Statements

Chairman and chief executive officer of Silexion, Ilan Hadar, said, “These findings have provided engaging evidence of SIL204’s potential activity against various KRAS mutations across multiple cancer types. The capability to achieve such a level of inhibition in colorectal and pancreatic cancer models with multiple KRAS mutations exponentially strengthens SIL204’s ability as a pa-KRAS therapeutic candidate. With these positive results in all three crucial KRAS-targeted cancer types, such as lung, pancreatic, and colorectal, we are elevating our confidence in SIL204’s potency to identify major unmet needs for severe cancer patients.”

P.S. – This revelation came right after Silexion projected the prominent efficacy of SIL204 in lung cancer cell lines. This is a validation of the company’s advanced lipid-conjugated delivery system. These results together across lung, pancreatic, and colorectal models showcase robust evidence of SIL204’s vast consideration aspect against KRAS-targeted cancers.

Silexion continues with the preparations for phase2/3 clinical trial in Q2 2026 to examine SIL204 for KRAS treatment of solid tumor cancers, accelerating systemic delivery and intratumoral approaches, considering it as a part of the company’s dual-path administration strategy.